Neuville / New York / Paris / Grosso do Sul / Lyon / /
Company
The New England Journal / Genzyme / Sanofi / Sanofi Pasteur / /
Continent
Asia / Americas / /
Country
Puerto Rico / Mexico / Honduras / Thailand / Colombia / Indonesia / France / Malaysia / Brazil / Vietnam / Philippines / /
Currency
EUR / /
Event
FDA Phase / Company Listing Change / /
IndustryTerm
healthcare / therapeutic solutions / consumer healthcare / health care systems / health systems / diabetes solutions / /
MedicalCondition
severe dengue / next vaccine-preventable disease / symptomatic dengue disease / dengue infections / novel tetravalent dengue / epidemics / MS / severe disease / infections / dengue haemorrhagic fever / disease / diabetes / S0140WHO Dengue / infectious diseases / Dengue / symptomatic virologically-confirmed dengue / common infectious diseases / safe and effective dengue / respiratory distress / /
MedicalTreatment
immunization / vaccination / vaccinations / /
Organization
World Health Organization / American Society of Tropical Medicine and Hygiene / General Carlos Slim Foundation / /
Person
Rivaldo Cunha / Olivier Charmeil / Roberto Tapia-Conyer / /
Position
candidate in development / principal investigator / global healthcare leader / leader / Director / President and CEO / Infectious Disease Specialist / Associate Professor / /
Product
Latin America / dengue / Dengue vaccine / Sanofi Pasteur / /
PublishedMedium
New England Journal of Medicine / The New England Journal of Medicine / /
PRESS RELEASE The New England Journal of Medicine Publishes Results of Final Landmark Phase III Efficacy Clinical Study of Sanofi Pasteur’s Dengue Vaccine Candidate - Study successfully met primary objective and confi